Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate Mofetil/Mycophenolic Acid
Other: Placebo
Drug: Obinutuzumab
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2015-09-15

Last Posted Date: 2024-08-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 126

Registration Number: NCT02550652

Locations: 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸
Univ of California, San Diego, La Jolla, California, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 43 locations

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Phase 1

Completed

Conditions: Stage I Follicular Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
Stage III Follicular Lymphoma
Composite Lymphoma
Grade 3b Follicular Lymphoma
Stage I Diffuse Large B-Cell Lymphoma
Stage II Follicular Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma
Stage IV Follicular Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-09-04

Last Posted Date: 2020-10-14

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02541565

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Withdrawn

Conditions: Recurrent T Lymphoblastic Leukemia/Lymphoma
B Lymphoblastic Lymphoma
Recurrent B Lymphoblastic Lymphoma
Refractory T Lymphoblastic Lymphoma
T Lymphoblastic Lymphoma
B Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia

Interventions: Drug: Asparaginase
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Imatinib Mesylate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-09-02

Last Posted Date: 2018-11-14

Lead Sponsor: University of Washington

Registration Number: NCT02538926

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression

Phase 4

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Prednisone

First Posted Date: 2015-08-27

Last Posted Date: 2021-04-30

Lead Sponsor: University of British Columbia

Target Recruit Count: 40

Registration Number: NCT02534402

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada

The Research of Standard Diagnosis and Treatment for HSPN in Children

Phase 2

Conditions: Henoch-Schoenlein Purpura Nephritis

Interventions: Drug: Prednisone
Drug: Cyclophosphamide(CTX)
Drug: Mycophenolate mofetil(MMF)
Drug: Leflunomide(LEF)
Drug: Angiotensin-converting enzyme inhibitor(ACEI)
Drug: Methylprednisolone